Clinical and Treatment Characteristics of Patients Treated with the First Therapeutic Oncology Biosimilars Bevacizumab-awwb and Trastuzumab-anns in the US

TY - JOUR

T1 - Clinical and Treatment Characteristics of Patients Treated with the First Therapeutic Oncology Biosimilars Bevacizumab-awwb and Trastuzumab-anns in the US

AU - Mahtani, Reshma

N1 - Initial evidence from the first 12 months following market entry suggests rapid clinical adoption of bevacizumab-awwb and trastuzumab-anns across all approved tumor types. Usage of these two biosimilars was observed in both RP-naïve patients and patients who were previously treated with RP, with no ...

PY - 2021/9/1

Y1 - 2021/9/1

UR - https://pubmed.ncbi.nlm.nih.gov/35003333/

M3 - Article

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

ER -